Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma

Oral Oncol. 2024 Oct 3:159:107065. doi: 10.1016/j.oraloncology.2024.107065. Online ahead of print.

Authors

Wei-Zhen Tang¹, Wei-Ze Xu², Tai-Hang Liu³

Affiliations

¹ Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China. Electronic address: [email protected].
² Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China.
³ Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China. Electronic address: [email protected].

PMID: 39366057
DOI: 10.1016/j.oraloncology.2024.107065

No abstract available

Publication types

Letter